Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization.

We identified regulator of G-protein signaling-5 (RGS-5) as an angiogenic pericyte marker at sites of physiologic and pathologic angiogenesis. In a mouse model of pancreatic islet cell carcinogenesis, RGS-5 is specifically induced in the vasculature of premalignant lesions during the "angiogenic switch" and further elevated in tumor vessels. Similarly, RGS-5 is overexpressed in highly angiogenic astrocytomas but not in hypoxia-inducible factor-1alpha (HIF-1alpha)-deficient tumors, which grow along preexisting brain capillaries without inducing neovessels. Elevated levels of RGS-5 in pericytes are also observed during wound healing and ovulation indicating a strong correlation between RGS-5 expression and active vessel remodeling beyond tumor angiogenesis. Moreover, antitumor therapy, which reverses tumor vasculature to an almost normal morphology, results in down-regulation of RGS-5 transcription. Taken together, these data demonstrate for the first time a factor that is specific for "activated" pericytes. This further supports the notion that pericytes, like endothelial cells, undergo molecular changes during neovascularization that makes them a novel target for antiangiogenic therapy.

[1]  H. Fraser,et al.  Angiogenesis in the corpus luteum , 2003, Reproductive biology and endocrinology : RB&E.

[2]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[3]  S. Mizuno,et al.  A Culture Device Demonstrates that Hydrostatic Pressure Increases mRNA of RGS5 in Neuroblastoma and CHC1-L in Lymphocytic Cells , 2003, Cells Tissues Organs.

[4]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[5]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[6]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[7]  Per Lindahl,et al.  Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. , 2003, American Journal of Pathology.

[8]  C. Betsholtz,et al.  Pericyte‐specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  S. Schwartz,et al.  Expression Profiling Identifies 147 Genes Contributing to a Unique Primate Neointimal Smooth Muscle Cell Phenotype , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[11]  G. Hämmerling,et al.  Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. , 2002, Cancer research.

[12]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[13]  G. Hämmerling,et al.  Transformation of the microvascular system during multistage tumorigenesis , 2002, International journal of cancer.

[14]  K. Kinzler,et al.  Cell surface tumor endothelial markers are conserved in mice and humans. , 2001, Cancer research.

[15]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[16]  M. Wellner,et al.  Altered gene expression in cerebral capillaries of stroke-prone spontaneously hypertensive rats , 2001, Brain Research.

[17]  S. Maxwell,et al.  Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. , 2001, Journal of cell science.

[18]  R. Klein,et al.  Ephrin-B Reverse Signaling Is Mediated by a Novel PDZ-RGS Protein and Selectively Inhibits G Protein–Coupled Chemoattraction , 2001, Cell.

[19]  J. Clements,et al.  Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display , 2000, International journal of cancer.

[20]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[21]  M. Farquhar,et al.  The regulator of G protein signaling family. , 2000, Annual review of pharmacology and toxicology.

[22]  J. T. ten Cate,et al.  Hemostasis, Thrombosis, and Vascular Biology Vascular Endothelial Genes That Are Responsive to Tumor Necrosis Factor-␣ in Vitro Are Expressed in Atherosclerotic Lesions, including Inhibitor of Apoptosis Protein-1, Stannin, and Two Novel Genes , 1998 .

[23]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[24]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[25]  E. Butcher,et al.  Regulation of Chemotactic and Proadhesive Responses to Chemoattractant Receptors by RGS (Regulator of G-protein Signaling) Family Members* , 1998, The Journal of Biological Chemistry.

[26]  D. Hanahan,et al.  Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. , 1998, Cancer research.

[27]  K. Hirschi,et al.  PDGF, TGF-β, and Heterotypic Cell–Cell Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate , 1998, The Journal of cell biology.

[28]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[29]  E. Nestler,et al.  Regulators of G-Protein Signaling (RGS) Proteins: Region-Specific Expression of Nine Subtypes in Rat Brain , 1997, The Journal of Neuroscience.

[30]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[31]  Jiahuai Han,et al.  Characterization of a Novel Mammalian RGS Protein That Binds to Gα Proteins and Inhibits Pheromone Signaling in Yeast* , 1997, The Journal of Biological Chemistry.

[32]  K. Hirschi,et al.  Pericytes in the microvasculature. , 1996, Cardiovascular research.

[33]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[34]  G. Groenewegen,et al.  Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. , 1996, Blood.

[35]  R. Clark,et al.  Wound repair in the context of extracellular matrix. , 1994, Current opinion in cell biology.

[36]  E. Butcher,et al.  Dissection of murine lymphocyte-endothelial cell interaction mechanisms by SV-40-transformed mouse endothelial cell lines: novel mechanisms mediating basal binding, and alpha 4-integrin-dependent cytokine-induced adhesion. , 1991, Experimental cell research.

[37]  D. Ruiter,et al.  Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. , 1991, The American journal of pathology.

[38]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[39]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[40]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.